NCI Funding for HIV and AIDS Malignancies Research

Translational Research Toward Development of a Kaposi Sarcoma Herpesvirus (KSHV) Vaccine 

Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute intends to support basic and translational research that will guide the development of a prophylactic or therapeutic Kaposi sarcoma herpesvirus (KSHV) vaccine. A prophylactic KSHV vaccine could prevent primary KSHV infection, transmission, and subsequent development of KS and other KSHV-associated syndromes such as multicentric Castleman disease (MCD), primary effusion lymphoma (PEL), and KSHV inflammatory cytokine syndrome (KICS), or ameliorate the severity of disease.

Additional Information:
Translational Research Toward Development of a Kaposi Sarcoma Herpesvirus (KSHV) Vaccine
(U01 Clinical Trial Optional)

Implementation Science for Cancer Control in People Living with HIV in Low- and Middle-Income Countries

The purpose of this Notice of Funding Opportunity (NOFO) is to support Implementation Science for Cancer Control in People Living with HIV (PLWH) in Low- and Middle-Income Countries (LMICs) to accelerate the integration of evidence-based cancer control interventions for PLWH by leveraging existing HIV treatment and prevention infrastructure.

Additional Information:
Implementation Science for Cancer Control in People Living with HIV in Low- and Middle-Income Countries (U01 Clinical Trial Optional)

Basic/Translational Research on Health Disparities in Underrepresented People Living with HIV (PLWH) and Cancer 

This funding opportunity announcement solicits projects that focus on the biological interactions of cancer health disparities in PLWH from underrepresented minority groups through basic mechanistic or translational studies to investigate how HIV interacts with health disparities to promote both non-AIDS and AIDS-defining cancer initiation, progression, and the resulting pathogenic disease sequelae.

Additional Information:
Basic/Translational Research on Health Disparities in Underrepresented People Living with HIV (PLWH) and Cancer (R01 Clinical Trial Not Allowed)
Basic/Translational Research on Health Disparities in Underrepresented People Living with HIV (PLWH) and Cancer (R21 Clinical Trial Not Allowed)

Catalyst Award for Early-Stage Investigators (ESIs) Pursuing Research on HIV Comorbidities, Coinfections, and Complications

This funding opportunity announcement (FOA) supports research from creative early stage investigators who propose highly innovative, pioneering studies with potential to open new areas in HIV/AIDS research related to coinfections, comorbidities, and complications.

Additional Information:
Catalyst Award for Early-Stage Investigators (ESIs) Pursuing Research on HIV Comorbidities, Coinfections, and Complications (DP1-Clinical Trial Optional)

The role of Epstein Barr Virus (EBV) infection in Non- Hodgkin Lymphoma (NHL) and Hodgkin disease (HD) development with or without an underlying HIV infection

This funding opportunity announcement (FOA) focuses on the role of EBV infection on Non-Hodgkin Lymphoma (NHL) and Hodgkin disease (HD) development with or without an underlying HIV infection. Research project U01s funded through this PAR will form a cooperative group, the Epstein Barr Virus associated Lymphoma Consortium (EALC).

Additional Information:
The role of Epstein Barr Virus (EBV) infection in Non-Hodgkin Lymphoma (NHL) and Hodgkin disease (HD) development with or without an underlying HIV infection (U01 Clinical Trial Optional)

Interventions for Stigma Reduction to Improve HIV/AIDS Prevention, Treatment and Care in Low- and Middle-Income Countries

The goals of this FOA is to solicit R01 applications for up to 3 years of support to develop and test interventions to reduce the impact of HIV-associated stigma on the prevention and treatment of HIV infection and/or AIDS, and the quality of life of People Living with HIV/AIDS (PLWH). The FOA will also support interventions to address the multiple intersecting stigmas and measurement of stigmas at individual levels. For example support intervention research on strategies to cope with the complex burden of stigmatization due to HIV and one or more comorbidities/coinfections.

Additional Information:
Interventions for Stigma Reduction to Improve HIV/AIDS Prevention, Treatment and Care in Low- and Middle-Income Countries (R01 Clinical Trial Optional)

HIV-associated Non-Communicable Diseases Research at Low- and Middle-Income Country Institutions

The goals of this program are to support locally relevant research in critical areas of HIV- associated non-communicable diseases (NCDs) at Low- and Middle-Income Country (LMIC) Institutions, to enhance research capacity, and to build a network of researchers both within and across LMICs to address this critical burden. NCI is interested in research projects aimed at identifying specific contributions of HIV infection and its potential interaction with other pathogens towards the development and pathogenesis of cancer, or provide information on the clinical outcomes in people living with HIV and cancer.

Additional Information:
HIV-associated Non-Communicable Diseases Research at Low- and Middle-Income Country Institutions (R21 Clinical Trial Optional)

Notice of Special Interest (NOSI): Research on HIV-associated Malignancies

The purpose of this Notice of Special Interest (NOSI) is to continue advancing our understanding of the risks, development, progression, diagnosis, and treatment of malignancies observed in individuals with an underlying human immunodeficiency virus (HIV) infection or acquired immunodeficiency syndrome (AIDS), which are now a leading cause of death of people with HIV (PWH). The NOSI calls for proposals that seek to identify specific contributions to HIV infection and it potential interaction with other oncogenic pathogens on the development and pathogenesis of these cancers, including studies that provide new information on the clinical outcomes of such cancers in PWH. 

The purpose of this NOSI is therefore aligned with OAR priorities of AIDS research and is specifically launched to foster cancer-focused research that addresses important gaps in knowledge for the control and treatment of cancer and cancer-related comorbidities among PWH. This is a continuation of NOT-CA-20-022,  "High" or "Medium" Priority AIDS Research on Non-AIDS-defining or AIDS-defining Cancers, which expired on January 8, 2023 , and is entitled, “Research on HIV-associated malignancies ” to reflect the most recent Office of AIDS Research priority guidelines.

Multidisciplinary Studies of HIV/AIDS and Aging

This initiative solicits applications at the intersection of HIV and aging.  NCI is interested in studies that help to understand how aging in the presence of chronic HIV infections affects risk, spectrum and biology of cancer.

Additional Information:
Multidisciplinary Studies of HIV/AIDS and Aging (R01 Clinical Trial Optional)
Multidisciplinary Studies of HIV/AIDS and Aging (R21 Clinical Trial Optional)